{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Experiences Evaluation Revision Amid Strong Market Performance
Madrigal Pharmaceuticals, Inc. has recently revised its evaluation amid changing market dynamics. The stock has shown impressive performance over the past year, significantly outperforming the S&P 500. Technical indicators present a mixed outlook, reflecting both bullish and cautious trends as the company continues to navigate the pharmaceutical landscape.
Is Madrigal Pharmaceuticals, Inc. technically bullish or bearish?
As of October 24, 2025, Madrigal Pharmaceuticals, Inc. shows a mildly bullish technical trend, supported by bullish weekly MACD and Bollinger Bands, despite mixed signals from other indicators, and has significantly outperformed the S&P 500 over the past year and three years.
Is Madrigal Pharmaceuticals, Inc. technically bullish or bearish?
As of October 24, 2025, Madrigal Pharmaceuticals, Inc. shows a mildly bullish trend with positive momentum from MACD and Bollinger Bands, though mixed signals from KST and Dow Theory indicate some short-term uncertainty.
Is Madrigal Pharmaceuticals, Inc. technically bullish or bearish?
As of October 24, 2025, Madrigal Pharmaceuticals, Inc. has a mildly bullish technical trend, supported by positive MACD and moving averages, despite mixed signals from the KST and Dow Theory, while significantly outperforming the S&P 500 over the past year and three years but underperforming in the short term.
Madrigal Pharmaceuticals Hits New 52-Week High of $463.48
Madrigal Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has experienced significant growth, with a notable increase in stock performance and net sales, despite currently operating at a loss. High institutional holdings indicate confidence in its fundamentals.
Madrigal Pharmaceuticals Achieves 114.43% Annual Growth, Marking It as a Multibagger Stock
Madrigal Pharmaceuticals, Inc. has recently undergone a revision in its score, reflecting its strong market performance and impressive financial metrics. The stock has outperformed the S&P 500 significantly over the past year, with remarkable growth in net sales and high institutional holdings, indicating robust investor confidence.
Madrigal Pharmaceuticals Hits New 52-Week High of $460.00
Madrigal Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company reported a remarkable growth in net sales and has posted positive results for two consecutive quarters, supported by high institutional holdings, indicating strong investor confidence.
Madrigal Pharmaceuticals Hits Day High with 8.43% Surge in Stock Price
Madrigal Pharmaceuticals, Inc. has seen a notable stock increase today, reaching an intraday high of USD 460.00. The company reported a remarkable 1353.76% rise in net sales in June and has shown strong operational performance with positive results over the last two quarters, supported by high institutional holdings.
Is Madrigal Pharmaceuticals, Inc. technically bullish or bearish?
As of August 21, 2025, Madrigal Pharmaceuticals, Inc. has a bullish technical trend, supported by positive MACD indicators, moving averages, and strong performance compared to the S&P 500, with year-to-date and one-year returns of 42.84% and 89.03%, respectively.
Is Madrigal Pharmaceuticals, Inc. overvalued or undervalued?
As of August 7, 2024, Madrigal Pharmaceuticals, Inc. is considered risky and overvalued due to significant negative financial metrics, including a Price to Book Value of 8.69, an EV to Sales ratio of 17.17, and a troubling ROE of -55.10%, despite outperforming the S&P 500 with a 535.91% return over three years.
Madrigal Pharmaceuticals, Inc. Reports Negative Financial Performance Amidst Mixed Results
Madrigal Pharmaceuticals reported a challenging financial quarter for June 2025, with significant operating losses despite achieving its highest net sales of USD 212.8 million. Key metrics showed some improvement, including reduced raw material costs and better inventory turnover, but profitability remains a concern with a negative return on capital employed.
Is Madrigal Pharmaceuticals, Inc. overvalued or undervalued?
As of August 7, 2024, Madrigal Pharmaceuticals is considered overvalued and risky, with a high price-to-book ratio of 8.69, negative EV to EBIT and EBITDA ratios, a return on equity of -55.10%, and a year-to-date stock performance of -8.29%, underperforming the S&P 500.
Is Madrigal Pharmaceuticals, Inc. technically bullish or bearish?
As of June 6, 2025, Madrigal Pharmaceuticals, Inc. shows a neutral technical stance with weak bearish signals, as weekly indicators are bearish while monthly indicators are mildly bearish, resulting in mixed signals overall.
Who are in the management team of Madrigal Pharmaceuticals, Inc.?
As of March 2022, the management team of Madrigal Pharmaceuticals, Inc. includes Dr. Paul Friedman (CEO), Dr. Rebecca Taub (President of R&D and CMO), and several independent directors: Dr. Frederick Craves, Mr. Kenneth Bate, Mr. James Daly, Mr. Keith Gollust, and Dr. Richard Levy. They oversee the company's strategic direction and operations.
What does Madrigal Pharmaceuticals, Inc. do?
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). As of March 2025, it reported net sales of $137 million and a net loss of $73 million, with a market cap of approximately $6.21 billion.
How big is Madrigal Pharmaceuticals, Inc.?
As of Jun 18, Madrigal Pharmaceuticals, Inc. has a market capitalization of $6.21 billion, with net sales of $317.38 million and a net profit of -$391.59 million over the latest four quarters. Shareholder's funds are $754.38 million, and total assets amount to $1.04 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
